U18666A

Catalog No.S9669 Batch:S966902

Technical Data

Formula

C₂₅H₄₂ClNO₂

Molecular Weight

424.06

CAS No.

3039-71-2

Solubility (25°C)*

In vitro

DMSO

85 mg/mL (200.44 mM)

Ethanol

85 mg/mL (200.44 mM)

Water

43 mg/mL (101.4 mM)

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	0.25mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	0.25mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	U18666A (U18) is an inhibitor of intra-cellular cholesterol transport that inhibits dengue virus entry and replication.
In vitro	Viral particles are trapped in the Lamp-1 positive late endosome/lysosome compartment when cells are treated with U18666A. In addition, viral replication is also affected by U18666A treatment. An additive anti-viral effect is found when C75, a fatty acid synthase inhibitor, is used in combination with U81666A, suggesting the role of cholesterol and fatty acid in DENV.^[1]
In vivo	When U18666A is administered to cats experimentally infected with type I FIPV, the development of FIP may be suppressed compared with the control group. However, the number of animals with FIP is too low to establish anti-viral effect of U18666A in cats. Two of the five control cats administered PBS alone develops FIP. Four of the five cats administered U18666A develops no signs of FIP. One cat that temporarily developed fever, has no other clinical symptoms, and no gross lesion is noted on an autopsy after the end of the experiment. The FIPV gene is detected intermittently in feces and saliva regardless of the development of FIP or administration of U18666A.^[2]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines BHK21 cells Concentrations 6.15 μM Incubation Time 48 h Method BHK21 cells are seeded with a cell density of 2×10⁴ cells/well into a 96 well plate 1 day before infection. NGC virus is added at a multiplicity of infection (MOI) of 1 in the presence of 2% FBS and is harvested from the cell supernatant 2 days post infection. Viral titer is quantified by plaque assay. For time of addition experiment of U18666A, cells are pretreated for 16 h with the compound, before virus is added to the cells (16 h pretreatment) or cells are pretreated for 16 h and the compound remained throughout the 48 h of infection (throughout). Alternatively, compound is added only during the 1st hour of infection where most of the entry and fusion occurred (1 h entry), or after the 1st hour of infection (after entry) for the remaining of the infection.
Animal Study:^{^[2]}	Animal Models SPF cats Dosages 2.5 mg/kg, 1.25 mg/kg Administration SC

Cell Assay:^{^[1]}

Cell lines
BHK21 cells
Concentrations
6.15 μM
Incubation Time
48 h
Method
BHK21 cells are seeded with a cell density of 2×10⁴ cells/well into a 96 well plate 1 day before infection. NGC virus is added at a multiplicity of infection (MOI) of 1 in the presence of 2% FBS and is harvested from the cell supernatant 2 days post infection. Viral titer is quantified by plaque assay. For time of addition experiment of U18666A, cells are pretreated for 16 h with the compound, before virus is added to the cells (16 h pretreatment) or cells are pretreated for 16 h and the compound remained throughout the 48 h of infection (throughout). Alternatively, compound is added only during the 1st hour of infection where most of the entry and fusion occurred (1 h entry), or after the 1st hour of infection (after entry) for the remaining of the infection.

Animal Study:^{^[2]}

Animal Models
SPF cats
Dosages
2.5 mg/kg, 1.25 mg/kg
Administration
SC

References

Selleck's U18666A has been cited by 1 publication

Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation [ Redox Biol, 2023, 63:102732]	PubMed: 37150151

Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation [ Redox Biol, 2023, 63:102732]

PubMed: 37150151

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.